Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 577Carcinoma, Non-Small-Cell Lung 491Ovarian Neoplasms 328Lung Neoplasms 208Fallopian Tube Neoplasms 153Neoplasms 152Stomach Neoplasms 128Esophageal Neoplasms 127Triple Negative Breast Neoplasms 125Neoplasm Metastasis 121Carcinoma, Ovarian Epithelial 115Squamous Cell Carcinoma of Head and Neck 96Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Head and Neck Neoplasms 78Esophageal Squamous Cell Carcinoma 77Adenocarcinoma of Lung 49Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 32Pancreatic Neoplasms 30Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Paclitaxel × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡